MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jitc-2023-007307

Медицинская библиотека · Journal for immunotherapy of cancer · 2023

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer.

Drobni Zsofia Dora, Gongora Carlos, Taron Jana, Suero-Abreu Giselle A, Karady Julia, Gilman Hannah K, Supraja Sama, Nikolaidou Sofia, Leeper Nicolas, Merkely Béla, Maurovich-Horvat Pal, Foldyna Borek, Neilan Tomas G

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Patients with lung cancer face a heightened risk of atherosclerosis-related cardiovascular events. Despite the strong scientific rationale, there is currently a lack of clinical evidence examining the impact of immune checkpoint inhibitors (ICIs) on the advancement of atherosclerosis in patients with lung cancer. The objective of our study was to investigate whether there is a correlation between ICIs and the accelerated progression of atherosclerosis among individuals with lung cancer.

METHODS

In this case-control (2:1 matched by age and gender) study, total, non-calcified, and calcified plaque volumes were measured in the thoracic aorta using sequential contrast-enhanced chest CT scans. Univariate and multivariate rank-based estimation regression models were developed to estimate the effect of ICI therapy on plaque progression in 40 cases (ICI) and 20 controls (non-ICI).

RESULTS

The patients had a median age of 66 years (IQR: 58-69), with 50% of them being women. At baseline, there were no significant differences in plaque volumes between the groups, and their cardiovascular risk profiles were similar. However, the annual progression rate for non-calcified plaque volume was 7 times higher in the ICI group compared with the controls (11.2% vs 1.6% per year, p=0.001). Conversely, the controls showed a greater progression in calcified plaque volume compared with the ICI group (25% vs 2% per year, p=0.017). In a multivariate model that considered cardiovascular risk factors, the use of an ICI was associated with a more substantial progression of non-calcified plaque volume. Additionally, individuals treated with combination ICI therapy exhibited greater plaque progression.

CONCLUSIONS

ICI therapy was associated with more non-calcified plaque progression. These findings underscore the importance of conducting studies aimed at identifying the underlying mechanisms responsible for plaque advancement in patients undergoing ICI treatment.

TRIAL REGISTRATION NUMBER: NCT04430712.

Для цитирования: Drobni Zsofia Dora, Gongora Carlos, Taron Jana, Suero-Abreu Giselle A, Karady Julia, Gilman Hannah K, Supraja Sama, Nikolaidou Sofia, Leeper Nicolas, Merkely Béla, Maurovich-Horvat Pal, Foldyna Borek, Neilan Tomas G. Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer.. Journal for immunotherapy of cancer. 2023. DOI: 10.1136/jitc-2023-007307.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.